AI Engines For more Details: Perplexity Kagi Labs You
Cognitive Enhancement: Aniracetam is primarily known for its cognitive-enhancing effects. It is believed to modulate neurotransmitter systems in the brain, including acetylcholine, glutamate, and dopamine, which are involved in learning, memory, and cognition.
Memory Improvement: Some research suggests that aniracetam may enhance memory formation and retrieval. It may improve both short-term and long-term memory, as well as working memory, which is important for tasks that require active processing of information.
Attention and Focus: Aniracetam may also improve attention span, concentration, and focus. It is thought to enhance cholinergic transmission in the brain, which can support sustained attention and mental clarity.
Neuroprotective Effects: There is evidence to suggest that aniracetam has neuroprotective properties, meaning it may help protect neurons from damage and promote neuronal health. This could potentially be beneficial in neurodegenerative conditions or following brain injury.
Mood Enhancement: Some users report mood-enhancing effects with aniracetam use, including reduced anxiety and improved mood regulation. It may exert anxiolytic (anti-anxiety) effects by modulating glutamate receptors and GABAergic neurotransmission.
Potential Medical Uses: While aniracetam is not approved for the treatment of specific medical conditions, it has been studied for its potential therapeutic benefits in conditions such as Alzheimer's disease, cognitive impairment, and mood disorders. However, more research is needed to establish its efficacy and safety for these indications.
Dosage and Administration: Aniracetam is typically taken orally in the form of capsules or powder. The recommended dosage can vary depending on individual factors and desired effects. It is important to follow dosage instructions provided by healthcare professionals or product labeling.
Safety and Side Effects: Aniracetam is generally considered safe when used as directed. Common side effects may include headache, nausea, dizziness, and gastrointestinal discomfort. Adverse effects are usually mild and transient.
Interactions: Aniracetam may interact with certain medications or supplements. It is important to consult with a healthcare provider before using aniracetam, especially if you are taking other medications or have underlying health conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.6 | -1 |
| ADHD | 1.5 | 1.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 2.2 | 0.8 | 1.75 |
| Allergies | 2.5 | 0.6 | 3.17 |
| Allergy to milk products | 0.3 | 1.3 | -3.33 |
| Alzheimer's disease | 3.5 | 2.3 | 0.52 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0 | 0 |
| Ankylosing spondylitis | 1.2 | 0.9 | 0.33 |
| Anorexia Nervosa | 0.7 | 1.1 | -0.57 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 1.4 | 0.6 | 1.33 |
| Atherosclerosis | 1.1 | 0.7 | 0.57 |
| Atrial fibrillation | 1.5 | 1.6 | -0.07 |
| Autism | 3.7 | 3.1 | 0.19 |
| Autoimmune Disease | 0.9 | 0.9 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1.6 | 1.6 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 2.5 | 0.7 | 2.57 |
| Celiac Disease | 1.5 | 1 | 0.5 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 1.7 | 1 | 0.7 |
| Chronic Kidney Disease | 2.2 | 0.9 | 1.44 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.6 | 0.83 |
| Chronic Urticaria (Hives) | 0.9 | 0.5 | 0.8 |
| Coagulation / Micro clot triggering bacteria | 1.3 | 0.3 | 3.33 |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 4.8 | 0.6 | 7 |
| Constipation | 1.3 | 1.3 | |
| Coronary artery disease | 1.2 | 0.8 | 0.5 |
| COVID-19 | 3.1 | 2 | 0.55 |
| Crohn's Disease | 4.2 | 1.5 | 1.8 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.6 | 0.3 | 1 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 1.4 | 0.6 | 1.33 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 4.1 | 1.6 | 1.56 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.5 | 0.8 | 0.88 |
| Endometriosis | 1.6 | 0 | 0 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2 | 0.7 | 1.86 |
| erectile dysfunction | 1.8 | 1.8 | |
| Fibromyalgia | 0.7 | 1.2 | -0.71 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 1.8 | 0.39 |
| gallstone disease (gsd) | 1.9 | 0.3 | 5.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.3 | 4 |
| Generalized anxiety disorder | 1.8 | 0.6 | 2 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 1.2 | |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.3 | 0.5 | -0.67 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 1.7 | 1.2 | 0.42 |
| Heart Failure | 2.3 | 0.4 | 4.75 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0 | 0 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.6 | 0.7 | -0.17 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.2 | 1.3 | 0.69 |
| Hypothyroidism | 0.9 | 0.9 | |
| Hypoxia | 1.3 | 1.3 | |
| IgA nephropathy (IgAN) | 1.3 | 0.8 | 0.63 |
| Inflammatory Bowel Disease | 3.8 | 1.4 | 1.71 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 2.9 | 1.8 | 0.61 |
| ischemic stroke | 1 | 0.9 | 0.11 |
| Liver Cirrhosis | 2.7 | 1.2 | 1.25 |
| Long COVID | 2.9 | 1.3 | 1.23 |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.2 | 1.2 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.6 | 0.3 | 1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 3.1 | 2.9 | 0.07 |
| Mood Disorders | 3.6 | 1.6 | 1.25 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 3.1 | 1.5 | 1.07 |
| Multiple system atrophy (MSA) | 0.5 | 0.5 | |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.3 | 1.3 | -3.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 0.3 | 5 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.1 | 2.4 | 0.29 |
| obsessive-compulsive disorder | 2.9 | 1.5 | 0.93 |
| Osteoarthritis | 2.2 | 0.6 | 2.67 |
| Osteoporosis | 0.9 | 0.6 | 0.5 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 3 | 2.7 | 0.11 |
| Polycystic ovary syndrome | 3.1 | 0.9 | 2.44 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 1 | -2.33 |
| Primary sclerosing cholangitis | 1.8 | 0.8 | 1.25 |
| Psoriasis | 0.8 | 0.7 | 0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.1 | 1.27 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 2.6 | 0.7 | 2.71 |
| scoliosis | 0 | 0.3 | 0 |
| Sjögren syndrome | 1.3 | 1.2 | 0.08 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1 | 0.7 | 0.43 |
| Systemic Lupus Erythematosus | 3 | 0.1 | 29 |
| Tic Disorder | 0.7 | 0.7 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.3 | 1 | 1.3 |
| Type 2 Diabetes | 3.7 | 2.6 | 0.42 |
| Ulcerative colitis | 3.1 | 2.3 | 0.35 |
| Unhealthy Ageing | 3.3 | 0.4 | 7.25 |
| Vitiligo | 1.5 | 0.4 | 2.75 |
